查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球基因载体市场研究报告 - 行业分析、规模、份额、增长、趋势及2023至2030年预测
市场调查报告书
商品编码
1305196

全球基因载体市场研究报告 - 行业分析、规模、份额、增长、趋势及2023至2030年预测

Global Gene Vector Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030
出版日期: | 出版商: Value Market Research | 英文 240 Pages | 商品交期: 最快1-2个工作天内

价格

据预测，到2030年，全球基因载体市场需求将从2022年的993.72百万美元达到近3160.79百万美元，2023-2030年的复合年增长率为13.72%。

基因载体是一种用于将遗传物质转移到细胞、组织或器官中以改变或替换其遗传组成的工具。基因载体通常用于基因工程、基因治疗和生物技术研究。基因载体有多种类型，包括病毒载体和非病毒载体。病毒载体来源于病毒，可用于将遗传物质高效地传递给细胞。病毒载体的例子包括逆转录病毒、腺病毒和慢病毒。另一方面，非病毒载体通常由DNA或RNA制成，效率低于病毒载体。非病毒载体的例子包括质粒、脂质体和纳米颗粒。基因载体应用广泛，包括基因治疗，用于向细胞传递健康基因以治疗遗传疾病。基因载体还用于研究基因功能、创建转基因生物和开发新的生物技术产品。

市场动态：

癌症、囊性纤维化和镰状细胞性贫血等遗传疾病发病率的上升推动了对基因载体的需求。基因载体用于基因治疗，这是一种通过向细胞传递健康基因来治疗遗传疾病的有效方法。基因治疗技术的不断进步，如开发更安全、更高效的基因载体，推动了基因载体市场的增长。这包括病毒载体的使用，如慢病毒和腺相关病毒，它们具有更好的安全性和有效性。政府、私营公司和研究机构对基因治疗研究进行了大量投资。这推动了新型基因疗法的开发，并将基因载体作为提供这些疗法的关键工具。个性化医疗，即根据个人的特定基因组成进行治疗，是医疗保健领域日益增长的趋势。基因载体是提供个性化医疗的重要工具，这也推动了基因载体的应用。患者、医疗服务提供者和监管机构对基因疗法的认识和接受程度不断提高。这推动了基因载体作为基因治疗关键工具的应用。

研究报告包括波特五力模型、市场吸引力分析和价值链分析。这些工具有助于在全球范围内清晰地了解行业结构和评估竞争吸引力。此外，这些工具还对全球基因载体市场的各个细分市场进行了全面评估。基因载体行业的增长和趋势为本研究提供了整体方法。

市场细分：

基因载体市场报告的这一部分提供了国家和地区层面细分市场的详细数据，从而帮助战略家确定各自产品或服务的目标人群以及即将到来的机会。

按载体类型

  • 慢病毒
  • 腺病毒
  • 腺相关病毒（AAV）
  • 质粒DNA
  • 其他载体

按应用分类

  • 基因治疗
  • 疫苗学
  • 其他应用

按疾病分类

  • 遗传性疾病
  • 癌症
  • 传染病
  • 其他疾病

按最终用户

  • 科学研究
  • CRO
  • CDMO
  • 其他（制药、生物技术公司）

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太、拉美、中东和非洲地区基因载体市场的当前和未来需求。此外，报告还重点分析了所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况以及全球竞争格局的深入分析。基因载体市场的主要企业包括Lonza、Merck KGaA、Oxford Biomedica、CGT Catapult、Charles River Laboratories、uniQure N.V.、FUJIFILM Diosynth Biotechnologies、Spark Therapeutics, Inc.本节包括竞争格局的整体观点，其中包括各种战略发展，如关键并购、未来能力、合作伙伴关系、财务概况、合作、新产品开发、新产品上市和其他发展。

目 录

第一章：前言

  • 报告描述
    • 报告目标
    • 目标受众
    • 独特销售主张（USP）和产品
  • 研究范围
  • 研究方法
    • 市场调研流程
    • 市场调研方法

第二章：执行摘要

  • 市场亮点
  • 全球市场概况

第三章：基因载体-行业分析

  • 简介 - 市场动态
  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 行业趋势
  • 波特五力分析
  • 市场吸引力分析
    • 按载体类型的市场吸引力分析
    • 市场吸引力分析：按应用
    • 按疾病分类的市场吸引力分析
    • 按最终用户的市场吸引力分析
    • 市场吸引力分析：按地区

第四章：价值链分析

  • 价值链分析
  • 原材料分析
    • 原材料清单
    • 原材料制造商列表
    • 主要原材料价格走势
  • 潜在买家名单
  • 营销渠道
    • 直接营销
    • 间接营销
    • 营销渠道发展趋势

第五章：Covid-19疫情影响分析

第六章：全球基因载体市场分析：按载体类型分类

  • 载体类型概述
  • 历史和预测数据
  • 载体类型分析
  • 慢病毒
  • 腺病毒
  • 腺相关病毒（AAV）
  • 质粒DNA
  • 其他载体

第七章 ：全球基因载体市场分析：按应用分类

  • 概述：按应用分类
  • 历史和预测数据
  • 分析：按应用
  • 基因治疗
  • 疫苗学
  • 其他

第八章：全球基因载体市场分析：按疾病分类

  • 疾病概述
  • 历史和预测数据
  • 疾病分析
  • 遗传性疾病
  • 癌症
  • 传染病
  • 其他疾病

第九章：全球基因载体市场分析：按最终用户分类

  • 终端用户概述
  • 历史和预测数据
  • 终端用户分析
  • 科学研究
  • CRO
  • CDMO
  • 其他（制药、生物技术公司）

第10章：全球基因载体市场分析：按地域划分

  • 地区前景
  • 地区介绍
  • 北美销售分析
    • 概述、历史及预测销售分析
    • 北美地区销售分析
    • 北美地区各国销售分析
    • 美国销售分析
    • 加拿大销售分析
    • 墨西哥销售分析
  • 欧洲销售分析
    • 概述、历史和预测销售分析
    • 欧洲销售分析
    • 欧洲各国销售分析
    • 英国销售分析
    • 法国销售分析
    • 德国销售分析
    • 意大利销售分析
    • 俄罗斯销售分析
    • 欧洲其他地区销售分析
  • 亚太地区销售分析
    • 概述、历史和预测销售分析
    • 亚太地区各细分市场销售分析
    • 亚太地区各国销售分析
    • 中国销售分析
    • 印度销售分析
    • 日本销售分析
    • 韩国销售分析
    • 澳大利亚销售分析
    • 亚太其他地区销售分析
  • 拉丁美洲销售分析
    • 概述、历史和预测销售分析
    • 拉丁美洲各细分市场销售分析
    • 拉丁美洲各国销售分析
    • 巴西销售分析
    • 阿根廷销售分析
    • 秘鲁销售分析
    • 智利销售分析
    • 拉丁美洲其他地区销售分析
  • 中东和非洲销售分析
    • 概述、历史和预测销售分析
    • 中东和非洲各细分市场销售分析
    • 中东和非洲国家销售分析
    • 沙特阿拉伯销售分析
    • 阿联酋销售分析
    • 以色列销售分析
    • 南非销售分析
    • 中东及非洲其他地区销售分析

第十一章 ：基因载体企业竞争格局

  • 基因载体市场竞争
  • 伙伴关系/合作/协议
  • 合併与收购
  • 新产品上市
  • 其他发展

第十二章 ：公司概况

  • 顶级公司份额分析
  • 市场集中度
  • Lonza
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Merck KGaA
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Oxford Biomedica
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • CGT Catapult
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Charles River Laboratories
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • uniQure N.V.
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • FUJIFILM Diosynth Biotechnologies
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展
  • Spark Therapeutics Inc.
    • 公司概况
    • 公司收入
    • 产品
    • 近期发展

*注：在公司概况中，财务细节和近期发展取决于可用性，如果是私营公司，则可能不包括在内。

Product Code: VMR112110627

The global demand for Gene Vector Market is presumed to reach the market size of nearly USD 3160.79 MN by 2030 from USD 993.72 MN in 2022 with a CAGR of 13.72% under the study period 2023 - 2030.

A gene vector is a tool used to transfer genetic material into cells, tissues, or organs in order to alter or replace their genetic makeup. Gene vectors are commonly used in genetic engineering, gene therapy, and biotechnology research. There are several types of gene vectors, including viral and non-viral vectors. Viral vectors are derived from viruses and can be used to deliver genetic material to cells in a highly efficient manner. Examples of viral vectors include retroviruses, adenoviruses, and lentiviruses. Non-viral vectors, on the other hand, are typically made from DNA or RNA and are less efficient than viral vectors. Examples of non-viral vectors include plasmids, liposomes, and nanoparticles. Gene vectors are used in a wide range of applications, including gene therapy, where they are used to deliver healthy genes to cells in order to treat genetic diseases. They are also used in research to study gene function, create transgenic organisms, and develop new biotechnology products.

Market Dynamics:

The rising incidence of genetic disorders, such as cancer, cystic fibrosis, and sickle cell anaemia, is driving the demand for gene vectors. Gene vectors are used in gene therapy, a promising approach for treating genetic disorders by delivering healthy genes to cells. Ongoing advancements in gene therapy technology, such as the development of safer and more efficient gene vectors, are driving the growth of the gene vector market. This includes the use of viral vectors, such as lentiviruses and adeno-associated viruses, which have improved safety and efficacy profiles. There is a significant amount of investment being made in gene therapy research by governments, private companies, and research institutions. This is driving the development of new gene therapies and the use of gene vectors as key tools in their delivery. Personalized medicine, which involves tailoring treatment to an individual's specific genetic makeup, is a growing trend in healthcare. Gene vectors are a critical tool in delivering personalized medicine, which is driving their adoption. There is increasing awareness and acceptance of gene therapy among patients, healthcare providers, and regulatory bodies. This is driving the adoption of gene vectors as a key tool in gene therapy.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gene vector. The growth and trends of gene vector industry provide a holistic approach to this study.

Market Segmentation:

This section of the gene vector market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vector Type

  • Lentivirus
  • Adenovirus
  • Adeno-Associated Virus (AAV)
  • Plasmid DNA
  • Others

By Application

  • Gene Therapy
  • Vaccinology
  • Others

By Disease

  • Genetic Disorder
  • Cancer
  • Infectious Disease
  • Others

By End-User

  • Scientific Research
  • CRO
  • CDMO
  • Others (Pharmaceutical, Biotechnology Companies)

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Gene Vector market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gene vector market include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . GENE VECTOR - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Vector Type
    • 3.7.2 Market Attractiveness Analysis By Application
    • 3.7.3 Market Attractiveness Analysis By Disease
    • 3.7.4 Market Attractiveness Analysis By End-user
    • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GENE VECTOR MARKET ANALYSIS BY VECTOR TYPE

  • 6.1 Overview by Vector Type
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Vector Type
  • 6.4 Lentivirus Historic and Forecast Sales by Regions
  • 6.5 Adenovirus Historic and Forecast Sales by Regions
  • 6.6 Adeno-associated Virus (AAV) Historic and Forecast Sales by Regions
  • 6.7 Plasmid DNA Historic and Forecast Sales by Regions
  • 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL GENE VECTOR MARKET ANALYSIS BY APPLICATION

  • 7.1 Overview by Application
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by Application
  • 7.4 Gene Therapy Historic and Forecast Sales by Regions
  • 7.5 Vaccinology Historic and Forecast Sales by Regions
  • 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL GENE VECTOR MARKET ANALYSIS BY DISEASE

  • 8.1 Overview by Disease
  • 8.2 Historical and Forecast Data
  • 8.3 Analysis by Disease
  • 8.4 Genetic Disorder Historic and Forecast Sales by Regions
  • 8.5 Cancer Historic and Forecast Sales by Regions
  • 8.6 Infectious Disease Historic and Forecast Sales by Regions
  • 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL GENE VECTOR MARKET ANALYSIS BY END-USER

  • 9.1 Overview by End-user
  • 9.2 Historical and Forecast Data
  • 9.3 Analysis by End-user
  • 9.4 Scientific Research Historic and Forecast Sales by Regions
  • 9.5 CRO Historic and Forecast Sales by Regions
  • 9.6 CDMO Historic and Forecast Sales by Regions
  • 9.7 Others (Pharmaceutical, Biotechnology Companies) Historic and Forecast Sales by Regions

10 . GLOBAL GENE VECTOR MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1. Overview, Historic and Forecast Sales Analysis
    • 10.3.2. North America By Segment Sales Analysis
    • 10.3.3. North America By Country Sales Analysis
    • 10.3.4. United State Sales Analysis
    • 10.3.5. Canada Sales Analysis
    • 10.3.6. Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1. Overview, Historic and Forecast Sales Analysis
    • 10.4.2. Europe by Segment Sales Analysis
    • 10.4.3. Europe by Country Sales Analysis
    • 10.4.4. United Kingdom Sales Analysis
    • 10.4.5. France Sales Analysis
    • 10.4.6. Germany Sales Analysis
    • 10.4.7. Italy Sales Analysis
    • 10.4.8. Russia Sales Analysis
    • 10.4.9. Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1. Overview, Historic and Forecast Sales Analysis
    • 10.5.2. Asia Pacific by Segment Sales Analysis
    • 10.5.3. Asia Pacific by Country Sales Analysis
    • 10.5.4. China Sales Analysis
    • 10.5.5. India Sales Analysis
    • 10.5.6. Japan Sales Analysis
    • 10.5.7. South Korea Sales Analysis
    • 10.5.8. Australia Sales Analysis
    • 10.5.9. Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1. Overview, Historic and Forecast Sales Analysis
    • 10.6.2. Latin America by Segment Sales Analysis
    • 10.6.3. Latin America by Country Sales Analysis
    • 10.6.4. Brazil Sales Analysis
    • 10.6.5. Argentina Sales Analysis
    • 10.6.6. Peru Sales Analysis
    • 10.6.7. Chile Sales Analysis
    • 10.6.8. Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1. Overview, Historic and Forecast Sales Analysis
    • 10.7.2. Middle East & Africa by Segment Sales Analysis
    • 10.7.3. Middle East & Africa by Country Sales Analysis
    • 10.7.4. Saudi Arabia Sales Analysis
    • 10.7.5. UAE Sales Analysis
    • 10.7.6. Israel Sales Analysis
    • 10.7.7. South Africa Sales Analysis
    • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE GENE VECTOR COMPANIES

  • 11.1. Gene Vector Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12 . COMPANY PROFILES OF GENE VECTOR INDUSTRY

  • 12.1. Top Company Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Lonza
    • 12.3.1. Company Overview
    • 12.3.2. Company Revenue
    • 12.3.3. Products
    • 12.3.4. Recent Developments
  • 12.4. Merck KGaA
    • 12.4.1. Company Overview
    • 12.4.2. Company Revenue
    • 12.4.3. Products
    • 12.4.4. Recent Developments
  • 12.5. Oxford Biomedica
    • 12.5.1. Company Overview
    • 12.5.2. Company Revenue
    • 12.5.3. Products
    • 12.5.4. Recent Developments
  • 12.6. CGT Catapult
    • 12.6.1. Company Overview
    • 12.6.2. Company Revenue
    • 12.6.3. Products
    • 12.6.4. Recent Developments
  • 12.7. Charles River Laboratories
    • 12.7.1. Company Overview
    • 12.7.2. Company Revenue
    • 12.7.3. Products
    • 12.7.4. Recent Developments
  • 12.8. uniQure N.V.
    • 12.8.1. Company Overview
    • 12.8.2. Company Revenue
    • 12.8.3. Products
    • 12.8.4. Recent Developments
  • 12.9. FUJIFILM Diosynth Biotechnologies
    • 12.9.1. Company Overview
    • 12.9.2. Company Revenue
    • 12.9.3. Products
    • 12.9.4. Recent Developments
  • 12.10. Spark Therapeutics Inc.
    • 12.10.1. Company Overview
    • 12.10.2. Company Revenue
    • 12.10.3. Products
    • 12.10.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

  •  Market Snapshot
  •  Drivers : Impact Analysis
  •  Restraints : Impact Analysis
  •  List of Raw Material
  •  List of Raw Material Manufactures
  •  List of Potential Buyers
  •  Analysis by Vector Type (USD MN)
  •  Lentivirus Market Sales by Geography (USD MN)
  •  Adenovirus Market Sales by Geography (USD MN)
  •  Adeno-associated Virus (AAV) Market Sales by Geography (USD MN)
  •  Plasmid DNA Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis Market by Application (USD MN)
  •  Gene Therapy Market Sales by Geography (USD MN)
  •  Vaccinology Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by Disease (USD MN)
  •  Genetic Disorder Market Sales by Geography (USD MN)
  •  Cancer Market Sales by Geography (USD MN)
  •  Infectious Disease Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Analysis by End-user (USD MN)
  •  Scientific Research Market Sales by Geography (USD MN)
  •  CRO Market Sales by Geography (USD MN)
  •  CDMO Market Sales by Geography (USD MN)
  •  Others (Pharmaceutical, Biotechnology Companies) Market Sales by Geography (USD MN)
  •  Global Gene Vector Market Sales by Geography (USD MN)
  •  North America Market Analysis (USD MN)
  •  United State Market Analysis (USD MN)
  •  Canada Market Analysis (USD MN)
  •  Mexico Market Analysis (USD MN)
  •  Europe Market Analysis (USD MN)
  •  Europe Market Estimate by Country (USD MN)
  •  United Kingdom Market Analysis (USD MN)
  •  France Market Analysis (USD MN)
  •  Germany Market Analysis (USD MN)
  •  Italy Market Analysis (USD MN)
  •  Russia Market Analysis (USD MN)
  •  Spain Market Analysis (USD MN)
  •  Rest of Europe Market Analysis (USD MN)
  •  Asia Pacific Market Analysis (USD MN)
  •  China Market Analysis (USD MN)
  •  Japan Market Analysis (USD MN)
  •  India Market Analysis (USD MN)
  •  South Korea Market Analysis (USD MN)
  •  Australia Market Analysis (USD MN)
  •  Rest of Asia Pacific Market Analysis (USD MN)
  •  Latin America Market Analysis (USD MN)
  •  Brazil Market Analysis (USD MN)
  •  Argentina Market Analysis (USD MN)
  •  Peru Market Analysis (USD MN)
  •  Chile Market Analysis (USD MN)
  •  Rest of Latin America Market Analysis (USD MN)
  •  Middle East & Africa Market Analysis (USD MN)
  •  Saudi Arabia Market Analysis (USD MN)
  •  UAE Market Analysis (USD MN)
  •  Israel Market Analysis (USD MN)
  •  South Africa Market Analysis (USD MN)
  •  Rest of Middle East and Africa Market Analysis (USD MN)
  •  Partnership/Collaboration/Agreement
  •  Mergers And Acquisition

LIST OF FIGURES

  •  Research Scope of Gene Vector Report
  •  Market Research Process
  •  Market Research Methodology
  •  Global Gene Vector Market Size, by Region (USD MN)
  •  Porters Five Forces Analysis
  •  Market Attractiveness Analysis by Vector Type
  •  Market Attractiveness Analysis by Application
  •  Market Attractiveness Analysis by Disease
  •  Market Attractiveness Analysis by End-user
  •  Market Attractiveness Analysis by Region
  •  Value Chain Analysis
  •  Global Market Analysis by Vector Type (USD MN)
  •  Lentivirus Market Sales by Geography (USD MN)
  •  Adenovirus Market Sales by Geography (USD MN)
  •  Adeno-associated Virus (AAV) Market Sales by Geography (USD MN)
  •  Plasmid DNA Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Application (USD MN)
  •  Gene Therapy Market Sales by Geography (USD MN)
  •  Vaccinology Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by Disease (USD MN)
  •  Genetic Disorder Market Sales by Geography (USD MN)
  •  Cancer Market Sales by Geography (USD MN)
  •  Infectious Disease Market Sales by Geography (USD MN)
  •  Others Market Sales by Geography (USD MN)
  •  Global Market Analysis by End-user (USD MN)
  •  Scientific Research Market Sales by Geography (USD MN)
  •  CRO Market Sales by Geography (USD MN)
  •  CDMO Market Sales by Geography (USD MN)
  •  Others (Pharmaceutical, Biotechnology Companies) Market Sales by Geography (USD MN)
  •  Global Market by Revenue
  •  North America Market by Revenue
  •  Europe Market by Revenue
  •  Asia Pacific Market by Revenue
  •  Latin America Market by Revenue
  •  Middle East & Africa Market by Revenue
  •  Recent Development in Industry
  •  Top Company Share Analysis

 * Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.